Latest news with #ElancoAnimalHealthIncorporated
Yahoo
30-03-2025
- Business
- Yahoo
Is Elanco Animal Health (ELAN) About to Explode?
We recently compiled a list of the 12 Stocks That Are About to Explode. In this article, we are going to take a look at where Elanco Animal Health Incorporated (NYSE:ELAN) stands against the other stocks that are about to explode. Despite the current headwinds and uncertainty (which also caused heightened volatility in the last 2 weeks), there are indications that the recent US stock market correction was short-lived, and the market could return to growth. Helping the stock market move higher was a rebound in February's retail sales, following a downward revision in January. The pattern of evolution hints that January's sluggishness was more weather-driven and had little to do with the general strength of the consumer. Yardeni Research recently expressed a strong belief that retail sales will move higher in March and April, supporting the economy. Also, the recent cuts in real GDP growth projections for the first quarter of 2025 by the Atlanta Fed are primarily driven by a minority of economic niches dependent on public spending, while the core economic sectors remain strong. With that being said, we are currently at a potential bottom of the market correction, which could represent a favorable moment to pick stocks that are about to explode. Insider trading, specifically purchases made by key executive officers and directors, can often signal future stock price appreciation. When insiders buy shares of their own company, it suggests that those with the most intimate knowledge of the firm's prospects view the stock as undervalued. Economic research supports this idea; for instance, Lakonishok and Lee (2001) found that insider buying tends to precede periods of higher-than-average returns, indicating that insider purchases provide meaningful predictive power regarding stock performance. Therefore, tracking insider transactions, particularly when top management is actively buying shares in companies that are at or near 52-week lows, may help investors anticipate stocks that are about to explode. READ ALSO: 10 Stocks Set to Explode in 2025 Insider trading signals become particularly relevant as the new Trump 2.0 regime has caused a plethora of industries to crash and trade near their lows – the tariff news cycle has become exhausting, causing uncertain capital spending plans on top of direct cuts to many government programs and spending. The policies of the new US administration could indeed have long-lasting effects on many industries, such as government contracting (the closure of USAID represents a giant erosion of the total addressable market). Here's what Treasury Secretary Scott Bessent recently said: 'The market and the economy have become hooked, become addicted, to excessive government spending, and there's going to be a detox period… Could we be seeing this economy that we inherited starting to roll a bit? Sure. Look, there's going to be a natural adjustment as we move away from public spending.' Despite major changes being made in some directions, we do not exclude the possibility that many companies, that reached new lows since the election day of November 2024, are mainly driven by investors' fears and uncertainty, which may or may not materialize. For instance, many healthcare stocks have been trading lower on fears that Republicans will start digging into Medicare/Medicaid reimbursement policies and potentially interfere with the revenue base of companies relying on those programs. In this context, watching for potential hidden signals from insiders (such as significant insider buying) may help clear out any uncertainty, fear, and doubts by providing a tangible indication of management's confidence in the company's future prospects. A farmer tending to a herd of cattle with Innovative Parasiticide and Vaccine Products. For this article, we used Insider Monkey's insider trading screener to find stocks with at least two insiders buying shares worth at least $100,000 in 2025. Then, we considered only the stocks that are at or near their 52-week low. Our belief is that at least two insiders buying a significant amount of stock while the share price is at or near the lows represents an increased probability that the bottom is in rear-view mirror. Finally, we compare the list with our proprietary Q4 2024 database of hedge funds' ownership and include in the article the top 12 stocks with the largest number of hedge funds that own the stock. Analysts' projections for each stock's upside potential were also included to assess their likelihood of significant growth. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().Analysts' Upside Potential as of March 27: 43.6% Elanco Animal Health Incorporated (NYSE:ELAN) is a global animal health company engaged in developing, manufacturing, and marketing pharmaceutical products and vaccines for companion animals (dogs and cats) and farm animals (cattle, poultry, swine, and fish). The company's portfolio includes products focused on disease prevention, therapeutic treatments, parasite control, nutritional health, and animal productivity enhancement. ELAN serves veterinarians, farmers, livestock producers, and pet owners worldwide, operating across key geographic markets, including North America, Europe, Asia-Pacific, and Latin America. With an upside potential of over 43%, ELAN is one of the stocks that are about to explode. Elanco Animal Health Incorporated (NYSE:ELAN) has delivered impressive results, marking six quarters of consecutive growth and achieving a notable 3% increase in constant currency sales for 2024. Looking ahead, the company anticipates an even stronger performance, forecasting organic growth of 4-6% in constant currency sales for 2025. Central to this optimistic outlook is ELAN's robust innovation portfolio, featuring six promising blockbuster products that are now projected to generate between $640 million and $720 million in revenue during 2025. Particularly notable is Experior, a standout in the farm animal segment, which has reached blockbuster status in the US. This accomplishment reinforces the company's dominant market position, where it currently holds leading rankings in the US across beef, poultry, and swine segments. In the pet health division, Elanco Animal Health Incorporated (NYSE:ELAN) is also accelerating growth with the launch of two significant new products. Credelio Quattro, introduced in January 2025, distinguishes itself by offering more comprehensive protection and faster tick elimination compared to its competitors. Concurrently, Zenrelia, the company's JAK inhibitor designed to treat atopic dermatitis, has demonstrated strong efficacy and already achieved approximately 30% penetration across roughly 8,000 veterinary clinics in the US. Despite these positive developments, Elanco Animal Health Incorporated (NYSE:ELAN) faces challenges such as considerable foreign exchange headwinds, which negatively affected both revenue and EBITDA during the fourth quarter of 2024. Furthermore, strategic decisions like the sale of the Aqua business to Merck and significant investments supporting new product launches have created uneven EBITDA distribution, shifting profitability toward the latter half of 2025. However, at least 2 insiders bought more than $100,000 worth of shares in 2025, which potentially suggests that the peak headwinds are in the rear-view mirror. Overall ELAN ranks 4th on our list of the 12 stocks that are about to explode. While we acknowledge the potential of ELAN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ELAN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks To Buy Now According to Billionaires Disclosure: None. This article is originally published at . Sign in to access your portfolio
Yahoo
27-02-2025
- Business
- Yahoo
Is Elanco Animal Health Incorporated (ELAN) the Best Low Price Pharma Stock to Invest In Right Now?
We recently compiled a list of the . In this article, we are going to take a look at where Elanco Animal Health Incorporated (NYSE:ELAN) stands against the other pharma stocks. Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the term "defensive" a step further than practically any other industry. Improvements in medical technology, medications, and therapeutic approaches have changed the course of patient care. As the need for quick results has grown, pharmaceutical corporations in particular have drawn much attention. Global pharmaceutical manufacturing was estimated to be worth $516.48 billion in 2022, according to a Grand View Research analysis. From 2023 to 2030, the industry is expected to expand at a compound annual growth rate (CAGR) of 7.63%. The biopharma industry now has the most extensive and varied clinical pipeline to date, thanks to decades of groundbreaking research. In 2012, there were 3,200 distinct medications under development; by 2022, that number had nearly doubled to 6,100. The average cost of producing a single treatment is over $1 billion, while just 14% of medications in clinical trials reach FDA clearance, according to MIT research. This could be a game-changer for AI. For instance, generative AI helps identify illness patterns in large data sets to determine the optimal medicine combinations while enabling researchers to investigate far more possible compounds than they could with conventional techniques. Additionally, according to PwC, AI-driven analytics and automation could cut operational costs by more than 30% and process timeframes by 60–70%. In a similar vein, the market has grown significantly due to consumer interest in weight-loss medications like Ozempic and Wegovy. According to a recent study in the scientific journal Addiction, GLP-1 medications may reduce the prevalence of alcohol and opioid addiction by as much as 50%. Additionally, these medications are being evaluated for Alzheimer's disease and other disorders that are frequently associated with obesity. The development of GLP-1s is becoming crucial for pharmaceutical businesses that want to be leaders in fields like cardiovascular and renal health. Competition with the leading companies in the anti-obesity business, which is expected to grow to $130 billion by 2030, is no longer the main emphasis. The possibility for additional participants to enter the field is growing along with the possible applications of GLP-1s. For example, the Swiss business Roche entered the weight-loss drug sweepstakes last year when it paid up to $3.1 billion to acquire California-based Carmot Therapeutics. The corporation wants to "fast-track" its anti-obesity medicines to regain faith in its pipeline and take a share of the weight-loss market. The pharmaceutical sector may appear to be flourishing at first glance. However, it has its own set of difficulties, just like every other industry. Compared to 2021, funding for biotech and pharmaceuticals fell by a sharp 48.6% last year. In 2022, the IPO market also saw a significant decline, with profits falling as a result of market volatility and instability. Many general investors were apprehensive of the spike in drug-developer initial public offerings (IPOs) in 2020 and 2021, which garnered about $46.5 billion, more than the total from the preceding eight years combined. Future initial public offerings (IPOs) are being closely watched due to the high-risk, high-reward nature of the biotech sector as well as macroeconomic and geopolitical issues that impact larger markets. However, as of September 3, drug developers had raised $2 billion through initial public offerings (IPOs) this year, a 24% increase over the same period in 2023. However, according to BNN Bloomberg, over two-thirds of these funds were raised in the first two months as a result of a spike in new listings. However, pharma companies' portion of U.S. IPO profits has decreased from 17% in February to 6.5%, with less than $800 million raised in the next six months. Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), emphasized increased funding in cell and gene therapies in 2024 in his opening remarks at the October 7 conference. Thirteen of the fifteen biggest pharmaceutical companies in the world by market capitalization, he said, now have an "active presence" in this area. Major pharmaceutical corporations are increasingly turning to cell and gene therapies to fill possible revenue shortages as many product patents are about to expire. Despite this enthusiasm, there has been a reduction in related patent filings, and the number of cell and gene therapy deals in the pharmaceutical industry fell by 38% in Q2 2024 compared to the same time in 2023. Nevertheless, the sector is appealing and should not be disregarded by investors. Our methodology involved selecting pharmaceutical sector stocks with a market capitalization exceeding $2 billion and a share price below $20. We then identified the stocks with the lowest share prices and verified their last closing prices using Yahoo Finance. Finally, we ranked these stocks in ascending order based on their closing price as of February 21st. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A farmer tending to a herd of cattle with Innovative Parasiticide and Vaccine Products. Share Price as of the Close of February 21: $11.02 Elanco Animal Health Incorporated (NYSE:ELAN) is an animal health company that delivers services and products that prevent and treat disease in pets and farm animals and stands sixth among the best low price pharma stocks to invest in right now. Cats, dogs, cattle, swine, poultry, and sheep are the main species that are served by its varied portfolio. Elanco Animal Health Incorporated (NYSE:ELAN) offers two categories of products: Pet Health and Farm Animal. The Pet Health portfolio focuses on immunizations, treatments, and parasiticides. Additionally, it sells products that provide defense against internal parasites, fleas, and ticks. The Farm Animal portfolio comprises a complex array of items with an emphasis on pigs, cattle, and poultry. Among them are Comforta, Catosal, Maxiban, Monteban, Rumensin, Experior, Baycox, and Denagard. Elanco Animal Health Incorporated (NYSE:ELAN) has shown tremendous growth potential and is strategically focused on optimizing its operations while advancing its creative product pipelines. Credelio Quattro's anticipated Q1 2025 introduction is anticipated to bolster the business's standing in the parasiticide market. Additionally, it is projected that Experior's robust performance—mainly in the heifer market—will play a major role in its expansion in 2025. The possible success of these products, along with the continued growth of Zenrelia, a JAK inhibitor that was introduced in late September 2024 to treat atopic dermatitis and pruritus in dogs, is anticipated to support revenue growth and further solidify Elanco Animal Health Incorporated's (NYSE:ELAN) position in the market over the coming years. Overall ELAN ranks 6th on our list of the best low price pharma stocks to invest in right now. While we acknowledge the potential of ELAN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ELAN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle
GREENFIELD, Ind., Feb. 25, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with South Dakota-based Medgene to leverage the company's innovative vaccine platform technology. The agreement includes commercialization of a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle. Medgene reports the vaccine has met all requirements of the U.S. Department of Agriculture's (USDA) platform technology guidelines and is in the final stages of review for conditional license approval. While the poultry industry has developed interventions and processes to reduce the spread or eradicate HPAI, those efforts have continued to be challenging as the current outbreak enters its fourth year. Dairy producers have worked quickly to protect their herds without the same tools and biosecurity options to tackle this devastating disease. The cross-species transmission of the disease into nearly 1,000 dairy herds across the U.S. since March 2024, along with zoonotic transmission to people, shows that more interventions are quickly needed. This virus is prevalent and predicted to persist over time, thus a cattle vaccine will be critical to slow virus spread between birds and cattle. "As egg prices soar and milk production wanes in infected dairies, the need for new solutions to curb disease spread is evident," says Jeff Simmons, President and CEO of Elanco Animal Health. "Elanco is pleased to partner with Medgene to bring customers options to fight this devastating disease and believes this product will become part of a routine vaccination protocol for the U.S. dairy industry. This partnership further strengthens our diverse dairy portfolio and advances our One Health platform of animal health solutions, not only benefitting our dairy customers, but helping curb disease spread for our poultry customers, and working to improve egg prices for consumers." "Medgene has an established reputation of supporting animal owners and their veterinarians with our USDA-licensed platform technology and bioinformatics software to design transformational vaccines. With our critically important H5N1 vaccine for dairy cattle in the final stages of approval, we're excited to partner with Elanco to quickly bring this much needed solution to U.S. dairies," said Mark Luecke, CEO of Medgene. The USDA previously approved Medgene's vaccine platform technology in cattle, allowing the company to accelerate H5N1 vaccine development. Medgene has existing vaccine manufacturing supply ready to deploy with the ability to support the U.S. dairy herd. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product approvals and launches and expectations for contractual relationships. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including whether and when the USDA completes its review, the USDA's determination about any conditional approval, market acceptance of the vaccine, our ability to market and sell the vaccine, competition with other solutions to address highly pathogenic avian influenza and additional factors that could cause actual results to differ materially from forward-looking statements described in the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Investor Contact: Tiffany Kanaga (765) 740-0314 Media Contact: Colleen Dekker (317) 989-7011 View original content to download multimedia: SOURCE Elanco Animal Health
Associated Press
30-01-2025
- Health
- Associated Press
Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
GREENFIELD, Ind., January 30, 2025 /3BL/ - Scratching, rubbing, chewing, licking. All signs of an irritated, itchy dog. With approximately 17 million U.S. dogs suffering from allergic skin disease, including atopic dermatitis, food allergies or flea sensitivity,1,2 these are the sounds too many pet parents and veterinarians hear. Today, Elanco Animal Health Incorporated (NYSE: ELAN), is introducing some of the first allergic dogs who have found zen and gotten back to normal by using Zenrelia. Zenrelia, which was approved by the U.S. Food and Drug Administration (FDA) and launched in September 2024, is a highly effective, convenient and safe once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. 'Our research shows that when pet owners see their dog at their worst levels of itch, they're concerned, stressed, frustrated and anxious,3' said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. 'Pet owners shouldn't allow allergic itch to disrupt zen for them or their pups. Zenrelia is designed to begin working from the very first dose4 and help get dogs back to normal.'5 In fact, a newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, described the findings of a randomized, clinical trial which compared Zenrelia to the leading JAK inhibitor, Apoquel, in over 300 allergic dogs. The full study findings can be found at: The Zenrelia label includes a boxed warning related to concurrent vaccine administration based on the results of a vaccine response study. It's important for veterinarians to read the entire package insert, including the Boxed Warning, before prescribing Zenrelia. Meet Some of the Faces of Zen According to a survey of pet owners, itchy dog owners are eager to get back to a normal life with their dogs, with 82% agreeing they dream of the day their itchy dog becomes normal again and they understand that effective treatment is part of that solution.2 With Zenrelia now widely available, Zenrelia has expanded beyond the clinical trial to helping dogs across the country—and their pet owners—find zen. These real-world results give hope to millions of pet parents whose pets suffer from itch. Hunter from Ohio, found his zen with Zenrelia. This eight-year-old Chocolate lab suffered with dermatitis most of his life and as he got older, his symptoms—especially licking at his feet and lower legs got worse. His pet parent, Cristy, a receptionist at a vet clinic, tried everything her veterinarian had recommended to bring Hunter relief. Hunter had an extensive regimen of injections every 3-4 weeks, medicated shampoos and wipes, antihistamines, and during parts of the year when he was worse, he was on steroids. Even with this intensive routine his symptoms were never fully controlled—until Hunter took Zenrelia. 'His back feet were pretty much naked up until his first joint and his front feet would be scabby and scaly from the constant licking,' Cristy said. 'It was really discouraging as his dog mom that I couldn't do anything to help him. He's so much more comfortable since being on Zenrelia. It's such a relief that he has relief.' According to Cristy, 'It's worth talking to your veterinarian to see if it's something that your dog would benefit from.' Individual results may vary and dogs should be up to date on vaccinations prior to starting Zenrelia. Trooper, a four-year-old Yorkshire Terrier, from Arizona, first got back to normal levels of itch when he participated in the Zenrelia clinical trial. When the trial concluded, the itch returned. His owner, Robin, was excited to get him back on the treatment now that Zenrelia is widely available. 'Allergies are something he's going to have to suffer with his whole life,' said Trooper's pet parent, Robin. 'Having a solution for his allergies is such a relief. It makes my heart happy that I will be able to afford it and give him the relief he deserves.' Lisa, pet mom to 9-year-old Yorkshire Terrier-Chihuahua mix Scrappy said she 'tried everything under the sun' to help bring Scrappy relief. Scrappy's itching reached the point he lost a significant amount of fur, he didn't want to play or go on walks and no one was getting a good night's rest. Lisa tried numerous treatment options and felt depleted knowing his itch was never fully controlled, until she tried Zenrelia. After two days on Zenrelia, his itch level improved and after eight weeks on Zenrelia, Lisa is happy and relieved to see Scrappy back to a normal dog. According to Lisa, his hair has re-grown, he's taking long walks and he's a happy boy. 'I was excited to get Trooper, Scrappy and some other patients started on Zenrelia as soon as it was available to order,' said Dr. Tom Lewis, veterinarian and founder of Dermatology for Animals, a group of veterinary dermatology clinics committed to caring for pets with allergies. 'Seeing these dogs get back to normal levels of itch and seeing the bond restored between the dog and pet parents is incredibly rewarding. Pet owners should contact their veterinarian and ask if Zenrelia is right for their dog.' Buckaroo, an eight-year-old mixed breed from Texas, tried numerous treatment options without relief, including steroids and immunotherapy–until his veterinarian recommended Zenrelia. The photos below show Buckaroo's skin before Zenrelia, after three weeks of treatment, and after eight weeks of treatment. His owner noted, 'he's now the happiest boy in the world and his energy levels have increased dramatically.' 'I've had the opportunity to use Zenrelia in my practice and it's helped several of my patients get back to normal levels of itch,' said Dr. Brittany Lancellotti, a veterinary dermatologist at Veterinary Skin and Ear in Los Angeles, California. 'In the fight against allergic dermatitis, I've found that every dog is different - it's great to have another effective treatment option in my toolbox.' 'I work with dermatologists around the country through the American College of Veterinary Dermatology,' said Dr. Andrew Rosenberg, dermatologist, and director of medical operations at Animal Dermatology Clinic in New York and President of the American College of Veterinary Dermatology (ACVD). 'It' great to have another tool in the toolbox especially for both new and severe cases.' Veterinarians in the U.S. can learn more and place orders for Zenrelia now at ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at INDICATIONS Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age. IMPORTANT SAFETY INFORMATION See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Dogs should not take Zenrelia for a time period before and after vaccination. Discuss your dog's vaccine schedule with your veterinarian. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs. Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Apoquel is a trademark of Zoetis Services, LLC. © 2025 Elanco or its affiliates. 1. AVMA Pet Ownership and Demographic Sourcebook 2022. 2. Elanco Animal Health. Data on File. 3. Elanco and FleishmanHillard TRUE Global Intelligence Survey. 4. Elanco Animal Health. Data on File. 5. Elanco Animal Health. Data on File. Media Contact Investor Contact
Yahoo
30-01-2025
- Health
- Yahoo
Meet the Faces of Zen: Elanco's Zenrelia(TM) (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
Hunter, Trooper, Scrappy and Buckaroo find zen by using Zenrelia Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet) GREENFIELD, IN / / January 30, 2025 / Scratching, rubbing, chewing, licking. All signs of an irritated, itchy dog. With approximately 17 million U.S. dogs suffering from allergic skin disease, including atopic dermatitis, food allergies or flea sensitivity,1,2 these are the sounds too many pet parents and veterinarians hear. Today, Elanco Animal Health Incorporated (NYSE:ELAN), is introducing some of the first allergic dogs who have found zen and gotten back to normal by using Zenrelia. Zenrelia, which was approved by the U.S. Food and Drug Administration (FDA) and launched in September 2024, is a highly effective, convenient and safe once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. "Our research shows that when pet owners see their dog at their worst levels of itch, they're concerned, stressed, frustrated and anxious,3" said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "Pet owners shouldn't allow allergic itch to disrupt zen for them or their pups. Zenrelia is designed to begin working from the very first dose4 and help get dogs back to normal."5 In fact, a newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, described the findings of a randomized, clinical trial which compared Zenrelia to the leading JAK inhibitor, Apoquel, in over 300 allergic dogs. The full study findings can be found at: The Zenrelia label includes a boxed warning related to concurrent vaccine administration based on the results of a vaccine response study. It's important for veterinarians to read the entire package insert, including the Boxed Warning, before prescribing Zenrelia. Meet Some of the Faces of Zen According to a survey of pet owners, itchy dog owners are eager to get back to a normal life with their dogs, with 82% agreeing they dream of the day their itchy dog becomes normal again and they understand that effective treatment is part of that solution.2 With Zenrelia now widely available, Zenrelia has expanded beyond the clinical trial to helping dogs across the country-and their pet owners-find zen. These real-world results give hope to millions of pet parents whose pets suffer from itch. Hunter from Ohio, found his zen with Zenrelia. This eight-year-old Chocolate lab suffered with dermatitis most of his life and as he got older, his symptoms-especially licking at his feet and lower legs got worse. His pet parent, Cristy, a receptionist at a vet clinic, tried everything her veterinarian had recommended to bring Hunter relief. Hunter had an extensive regimen of injections every 3-4 weeks, medicated shampoos and wipes, antihistamines, and during parts of the year when he was worse, he was on steroids. Even with this intensive routine his symptoms were never fully controlled. -until Hunter took Zenrelia. "His back feet were pretty much naked up until his first joint and his front feet would be scabby and scaly from the constant licking," Cristy said. "It was really discouraging as his dog mom that I couldn't do anything to help him. He's so much more comfortable since being on Zenrelia. It's such a relief that he has relief." According to Cristy, "It's worth talking to your veterinarian to see if it's something that your dog would benefit from." Individual results may vary and dogs should be up to date on vaccinations prior to starting Zenrelia. Trooper, a four-year-old Yorkshire Terrier, from Arizona, first got back to normal levels of itch when he participated in the Zenrelia clinical trial. When the trial concluded, the itch returned. His owner, Robin, was excited to get him back on the treatment now that Zenrelia is widely available. "Allergies are something he's going to have to suffer with his whole life," said Trooper's pet parent, Robin. "Having a solution for his allergies is such a relief. It makes my heart happy that I will be able to afford it and give him the relief he deserves." Lisa, pet mom to 9-year-old Yorkshire Terrier-Chihuahua mix Scrappy said she "tried everything under the sun" to help bring Scrappy relief. Scrappy's itching reached the point he lost a significant amount of fur, he didn't want to play or go on walks and no one was getting a good night's rest. Lisa tried numerous treatment options and felt depleted knowing his itch was never fully controlled, until she tried Zenrelia. After two days on Zenrelia, his itch level improved and after eight weeks on Zenrelia, Lisa is happy and relieved to see Scrappy back to a normal dog. According to Lisa, his hair has re-grown, he's taking long walks and he's a happy boy. "I was excited to get Trooper, Scrappy and some other patients started on Zenrelia as soon as it was available to order," said Dr. Tom Lewis, veterinarian and founder of Dermatology for Animals, a group of veterinary dermatology clinics committed to caring for pets with allergies. "Seeing these dogs get back to normal levels of itch and seeing the bond restored between the dog and pet parents is incredibly rewarding. Pet owners should contact their veterinarian and ask if Zenrelia is right for their dog." Buckaroo, an eight-year-old mixed breed from Texas, tried numerous treatment options without relief, including steroids and immunotherapy - until his veterinarian recommended Zenrelia. The photos below show Buckaroo's skin before Zenrelia, after three weeks of treatment, and after eight weeks of treatment. His owner noted, "he's now the happiest boy in the world and his energy levels have increased dramatically." "I've had the opportunity to use Zenrelia in my practice and it's helped several of my patients get back to normal levels of itch," said Dr. Brittany Lancellotti, a veterinary dermatologist at Veterinary Skin and Ear in Los Angeles, California. "In the fight against allergic dermatitis, I've found that every dog is different - it's great to have another effective treatment option in my toolbox." "I work with dermatologists around the country through the American College of Veterinary Dermatology," said Dr. Andrew Rosenberg, dermatologist, and director of medical operations at Animal Dermatology Clinic in New York and President of the American College of Veterinary Dermatology (ACVD). "It'S great to have another tool in the toolbox especially for both new and severe cases." Veterinarians in the U.S. can learn more and place orders for Zenrelia now at ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars - all to advance the health of animals, people, the planet and our enterprise. Learn more at INDICATIONS Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age. IMPORTANT SAFETY INFORMATION See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Dogs should not take Zenrelia for a time period before and after vaccination. Discuss your dog's vaccine schedule with your veterinarian. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs. Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Apoquel is a trademark of Zoetis Services, LLC. © 2025 Elanco or its affiliates. 1. AVMA Pet Ownership and Demographic Sourcebook 2022.2. Elanco Animal Health. Data on File.3. Elanco and FleishmanHillard TRUE Global Intelligence Survey.4. Elanco Animal Health. Data on File.5. Elanco Animal Health. Data on File. Media Contact Season Solorio +1.765.316.0233 Investor Contact Tiffany Kanaga +1.765.740.0314 Buckaroo before Zenrelia (left); Buckaroo after Zenrelia treatment (middle and right) View additional multimedia and more ESG storytelling from Elanco on Contact Info:Spokesperson: ElancoWebsite: info@ SOURCE: Elanco View the original press release on ACCESS Newswire Sign in to access your portfolio
